Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study

Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study

Objectives: HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. Materials and methods: This prospective, non-interventional study incl...

Full description

Bibliographic Details
Main Authors: Jean-Philippe Jacquin, Lionel Uwer, Alexia Savignoni, Jean-Marc Ferrero, Alain Lortholary, David Solub, Flore Delaporte, Nassera Chalabi, Sophie Pibre, Yazid Belkacemi
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Breast
Subjects:
HER2-Positive
Early breast cancer
Trastuzumab
Sub-cutaneous injection
SC
Safety profile
Online Access:http://www.sciencedirect.com/science/article/pii/S096097761930565X

Internet

http://www.sciencedirect.com/science/article/pii/S096097761930565X

Similar Items